TAVR using the self-expanding valve Evolut FX for Aortic Valve Stenosis
Study Summary
This trial aims to compare 2 types of mitral valve replacement, SEV & BEV, to see which is better in terms of blood flow & exercise capacity, using CMR for a more precise assessment.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Awards & Highlights
Trial Design
Find a site
Who is running the clinical trial?
Media Library
Frequently Asked Questions
Is the research team seeking out participants of a certain age for this clinical trial?
"The eligibility requirements of this trial are such that participants must be 18 to 105 years old. Separately, there exist 24 trials for minors and 161 studies specifically targeting seniors."
What impact is this medical experiment expected to produce?
"Over the course of a year, this study will seek to measure peak gradient as its primary objective. Secondary outcomes include exercise capacity post TAVR assessed by CMR (METs), left ventricle ejection fraction measured with transthoracic echocardiography (%), and mean gradient evaluated through transthoracic echocardiography (mmHg)."
Who qualifies as an eligible participant for this research study?
"Qualified candidates for this clinical trial must have aortic valve stenosis and be within the age bracket of 18-105. The research is looking to enrol 90 people in total."
Are there any vacancies for participants yet in this experiment?
"According to clinicaltrials.gov, this experiment is not currently taking on any new participants. The trial was originally posted January 1st 2023 and last edited November 1st 2022. Although it has closed its doors for recruitment, there are 161 other medical tests actively searching for volunteers as we speak."